• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Depression Treatment Breakthroughs

Scientists are attacking depression from different angles than before. These treatments are designed to aid in avoiding relapses and discover the right medication.

Psychotherapy is a viable option if antidepressants don't work. This includes cognitive behavioral therapy and interpersonal psychotherapy.

Deep Brain Stimulation

Deep brain stimulation is a surgical procedure that involves the use of electrodes within the brain are placed to target specific areas of the brain that can cause conditions and diseases like depression. The electrodes are connected to a device which emits electric pulses in order to treat the disease. The DBS device, also referred to as a neurostimulator, is used to treat other neurological disorders such as epilepsy and Parkinson's disease. The DBS device's pulsing may "jam up" circuits that trigger abnormal brain activity during depression, while leaving other circuits unaffected.

Clinical studies of DBS have shown significant improvements in patients with treatment resistant depression (TRD). Despite these positive results TRD recovery looks different for each patient. Clinicians rely on subjective reports from interviews with patients and psychiatric ratings scales that can be difficult for them to interpret.

Researchers from the Georgia Institute of Technology, Emory University School of Medicine, and the Icahn School of Medicine at Mount Sinai, have developed an algorithm that can detect subtle changes in brain activity patterns and can differentiate them from depressive versus stable recovery states. The study published in Nature Human Behaviour in Nature emphasizes the importance of combining neuroscience and medical disciplines with computer engineering to develop potentially life-changing treatments.

In DBS, doctors insert a thin wire-like lead into the brain through a tiny hole in the skull. The lead is equipped with a variety of electrodes at its tips that send electrical impulses to the brain. The lead is connected to an extension cable that runs from the head, through the ear and then down to the chest. The lead and extension are connected to an implanted battery-powered stimulator under the skin of your chest.

The neurostimulator that can be programmed generates electric pulses to regulate abnormal brain activity in the areas targeted by the DBS devices. In the study, the researchers used DBS to target a particular region of the brain called the subcallosal cingulate cortex (SCC). The scientists found that when SCC was stimulated, it resulted in an increase in dopamine levels, which can help alleviate symptoms of depression.

Brain Scanners

A doctor may employ various methods and tools to diagnose depression, but the best one to date is brain scans. This technology uses imaging to observe changes in brain activity on both the functional and structural levels. It can be used by a client to determine the affected regions of their brain, and then determine the state of these regions in real-time.

Brain mapping can help determine the type of holistic treatment for anxiety and depression is most effective for an individual. Certain people respond better to antidepressant medications than others. However this isn't always the case. Psychologists and physicians can prescribe medications more precisely when they utilize MRI to assess the effectiveness. It can also help to increase compliance by allowing patients to see how their treatment progresses.

Despite its widespread use, research in mental health has been hampered by the difficulty of assessing it. There is an abundance of information about depression, anxiety, and other conditions. However, it has been difficult to pinpoint the causes. However, the latest technology is beginning to reveal the mechanisms behind these conditions.

For instance, a study published in Nature Medicine sorts depression treatment without drugs into six distinct biological subtypes. This paves the way toward individualized treatment.

Researchers utilized fMRI to study brain activity in 801 people with depression and 137 who did not. Researchers examined the activation of brain circuits that are affected by depression, for instance those that control cognition or emotions. They looked at the brain scans of a subject in a state of rest and while completing specific tasks.

The results were that a combination of resting state and task-based measurements could be used to determine whether or not a person would react to SSRIs. This is the first time that a predictive test has been created in the field of psychiatry. The team is currently working on developing an automated test that will give these predictive results.

This is especially useful for those who don't respond to conventional treatments such as therapy and medication. In fact, as high as 60 percent of people with depression do not respond to the initial form of treatment they receive. Some of these patients are referred to as treatment-resistant and can be difficult to treat with a standard regimen, but the hope is that new technologies will help to improve treatment options.

Brain Implants

Sarah suffered from a severe form of depression. She described it as a blackhole that dragged her down. It was a force so strong that she was unable to move. She tried a range of medications, but none provided an enduring boost. She also had undergone other treatments like electroconvulsive therapy and ketamine injections however, they failed to work. Then, she decided to undergo a surgery that would permit researchers to implant electrodes into her brain to send her a specific shock whenever she was likely to suffer from a depressive attack.

The method, also known as deep brain stimulation is widely used to treat Parkinson's disease and has been proven to help those suffering from treatment-resistant depression. It is not a cure, but it helps the brain cope. It makes use of a device to implant small electrodes in specific areas of the brain, like a pacemaker.

In the study published in Nature Medicine on Monday, two researchers from the University of California at San Francisco describe how they used the DBS to customize depression treatment for a particular patient. They called it a new "revolutionary" method that could pave way for customized DBS therapies to be offered to other patients.

The team studied Sarah's brain's neuronal circuits and found that her amygdala is the main cause of her depression episodes. They found that the ventral region, the deepest part of her brain is responsible for calming her amygdala overreaction. They then implanted the matchbox-sized device in Sarah's brain and attached its electrode legs that resembled spaghetti to the two brain regions.

If a sign of depression occurs the device instructs Sarah's brain to send a tiny electrical charge to the amygdala as well as to the ventral striatum. The intention is to stop depression and motivate her to be more positive. It's not a cure however it can make a significant difference for those who need it the most. In the future, it could be used to identify the biological signs that indicates a depression is on the way, allowing doctors to prepare by turning up the stimulation.

Personalized Medicine

The concept of personalized medicine refers to adapting diagnosis, prevention and treatment strategies to individual patients based on the information obtained through molecular profiling, medical imaging, lifestyle data and more. This differs from traditional alternative treatments for depression designed for the average patient. It is one-size-fits-all solutions that may not be effective or efficient.

Recent studies have revealed a myriad of factors that can cause depression among different patients. These include genetic variation and neural circuitry malfunctions, biomarkers and psychosocial markers, among others. The goal of psychiatry that is personalized is to incorporate these findings into the clinical decision-making process to ensure the best treatment. It also aims to aid in the development and implementation of specific treatment plans for psychiatric issues like depression.

The field of individualized psychiatry continues to grow but there are a few obstacles still preventing its clinical application. Many psychiatrists are not familiar with the pharmacological profiles of antidepressants. This can lead to suboptimal prescribing. It is also essential to think about the cost and complexity of integrating multiomics into healthcare systems, as well as ethical concerns.

One promising avenue to advance the personalized psychiatry approach is pharmacogenetics. It aims at utilizing a individual's genetic makeup to determine the appropriate dose of medication. It has been suggested that this can aid in reducing adverse effects of drugs and boost treatment efficacy, especially in the case of SSRIs.

It is important to note that this is a possible solution and more research is required before it is widely used. Furthermore, other factors like lifestyle choices and environmental influences are important to take into consideration. The integration of pharmacogenetics into depression treatment must therefore be carefully considered.

Functional neuroimaging may also be used to guide the choice of antidepressants or psychotherapy. Studies have demonstrated that the pretreatment levels of certain neural circuits (e.g. ventral and pregenual anterior cingulate cortex) determine the response to both pharmacological and psychotherapeutic treatments. Additionally, certain clinical trials have already used these findings to guide their selection of participants, focusing on those with more activation levels and consequently having more favorable responses to therapy.